Objective To investigate the relationship between T lymphocyte subsets and the efficacy of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer.Methods The 60 patients with advanced non-small cell lung cancer admitted to the Third Affiliated Hospital of Qiqihar Medical College from January 2022 to January 2023 were selected as research subjects,and all of them received immunotherapy combined with chemotherapy.According to the treatment effect,the patients were divided into good treatment group(with complete response or partial response;22 cases)and poor treatment group(stable and progressive;38 cases).The proportions of CD3+T,CD4+T,CD8+T cells and CD4/CD8 ratio before and after treatment were compared.The receiver operator characteristic(ROC)curve was plotted and the area under ROC curve(AUC)was calculated to analyze the correlation between T lymphocyte subsets and the efficacy of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer.Results After two cycles of treatment,the proportion of CD8+T cells was significantly lower than that before treatment[(35.96±6.48)%vs.(42.37±12.26)%,P<0.05].After four cycles of treatment,CD4+T cell proportion and CD4/CD8 ratio were significantly higher than those after two cycles of treatment,and CD8+T cell proportion was significantly lower than that after two cycles of treatment[CD4+T cell proportion:(50.74±5.68)%vs.(46.22±8.25)%;CD4/CD8:1.55±0.21 vs.1.28±0.40;CD8+T cell proportion:(32.66±5.98)%vs.(35.96±6.48)%;all P<0.05].After four cycles of treatment,CD8+T cell proportion in patients with good efficacy was significantly lower than that in patients with poor efficacy,and CD4/CD8 ratio was significantly higher than that in patients with poor efficacy[CD8+T cell proportion:(33.26±4.12)%vs.(39.20±6.95)%;CD4/CD8:1.34±0.18 vs.1.21±0.15;both P<0.05].ROC curve analysis showed that after two cycles of treatment,the AUC of the proportions of CD4+T,CD8+T,CD3+T cells and CD4/CD8 ratio in patients with good efficacy were 0.430,0.260,0.610 and 0.590,respectively.After four cycles of treatment,the AUC of the proportions of CD4+T,CD8+T,CD3+T cells and CD4/CD8 ratio in patients with good efficacy were 0.350,0.020,0.480 and 0.880,respectively.Conclusion CD4/CD8 ratio in T lymphocyte subsets of patients with advanced non-small cell lung cancer is effective in evaluating the efficacy of immunotherapy combined with chemotherapy.
维普
万方数据